How different estrogen receptor forms affect lupus-related inflammation
The Role of Estrogen Receptor Alpha Variant Size and Localization in Modulating TLR7-Induced Inflammation
This research looks at whether a shorter form of the estrogen receptor can reduce immune-driven inflammation that contributes to lupus, particularly in females.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-11257689 on NIH RePORTER |
What this research studies
If you have lupus, this project is exploring how different versions of the estrogen receptor change immune cell behavior that drives inflammation. The team uses lupus-prone mice and lab-grown immune cells to compare the usual full-length receptor with a shorter variant and to study responses triggered by the TLR7 pathway. They focus on dendritic cells and kidney inflammation because earlier mouse work showed the short form reduced kidney disease and improved survival. The goal is to understand the biological mechanism so it can point to hormone-related treatment strategies.
Who could benefit from this research
Good fit: People living with systemic lupus erythematosus (especially females whose symptoms change with hormones) would be the most relevant group for future clinical follow-up of this work.
Not a fit: Patients without lupus or whose disease is driven by pathways unrelated to estrogen receptor signaling or TLR7 are unlikely to benefit directly from this specific line of research.
Why it matters
Potential benefit: If successful, the work could reveal a hormone-receptor target that leads to new therapies to reduce lupus flares or organ damage.
How similar studies have performed: Prior mouse and laboratory studies have shown that shorter estrogen receptor forms can protect against lupus-like disease and alter TLR responses, but this approach has not yet been proven in people.
Where this research is happening
Charleston, United States
- Medical University of South Carolina — Charleston, United States (Active)
Researchers
- Principal investigator: Cunningham, Melissa a — Medical University of South Carolina
- Study coordinator: Cunningham, Melissa a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.